HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: An unexpected effect on TRAIL-induced apoptosis

FEBS Letters

Volumn 579, Issue 19, 2005, Pages 4149-4158

  Dubská, Lenka ^a,b   Anděra, Ladislav ^c   Sheard, Michael Allen ^d  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Apoptosis; Breast cancer; HER2 neu; PI3K; TRAIL; Trastuzumab

Indexed keywords

CASPASE 8; CASPASE 9; DEATH RECEPTOR 4; DEATH RECEPTOR 5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOMYCIN C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN BID; PROTEIN KINASE B; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL TYPE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; FLUORESCENT ANTIBODY TECHNIQUE; GENES, ERBB-2; HUMANS; MEMBRANE GLYCOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 22544470606     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2005.06.047     Document Type: Article

References (61)

1. L.E. French, and J. Tschopp The TRAIL to selective tumor death Nat. Med. 5 1999 146 147
2. W.D. Thomas, and P. Hersey TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells J. Immunol. 161 1998 2195 2200
3. K. Takeda, M.J. Smyth, E. Cretney, Y. Hayakawa, N. Kayagaki, H. Yagita, and K. Okumura Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development J. Exp. Med. 195 2002 161 169
4. K. Takeda, M.J. Smyth, E. Cretney, Y. Hayakawa, N. Yamaguchi, H. Yagita, and K. Okumura Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth Cell. Immunol. 214 2001 194 200
5. G. Dorothee, I. Vergnon, J. Menez, H. Echchakir, D. Grunenwald, M. Kubin, S. Chouaib, and F. Mami-Chouaib Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: Role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity J. Immunol. 169 2002 809 817
6. F.C. Kischkel, D.A. Lawrence, A. Tinel, H. LeBlanc, A. Virmani, P. Schow, A. Gazdar, J. Blenis, D. Arnott, and A. Ashkenazi Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8 J. Biol. Chem. 276 2001 46639 46646
7. R. Takimoto, and W.S. El-Deiry Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site Oncogene 19 2000 1735 1743
8. R. Ravi, G.C. Bedi, L.W. Engstrom, Q. Zeng, B. Mookerjee, C. Gelinas, E.J. Fuchs, and A. Bedi Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB Nat. Cell. Biol. 3 2001 409 416
9. A.C. Spalding, R.M. Jotte, R.I. Scheinman, M.W. Geraci, P. Clarke, K.L. Tyler, and G.L. Johnson TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappaB-dependent, genotoxin-induced apoptosis of cancer cells Oncogene 21 2002 260 271
10. M.A. Degli-Esposti, P.J. Smolak, H. Walczak, J. Waugh, C.P. Huang, R.F. DuBose, R.G. Goodwin, and C.A. Smith Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family J. Exp. Med. 186 1997 1165 1170
11. M.A. Degli-Esposti, W.C. Dougall, P.J. Smolak, J.Y. Waugh, C.A. Smith, and R.G. Goodwin The novel receptor TRAIL-R4 induces NF-kappa-B and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain Immunity 7 1997 813 820
12. P. Schneider, M. Thome, K. Burns, J.L. Bodmer, K. Hofmann, T. Kataoka, N. Holler, and J. Tschopp TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB Immunity 7 1997 831 836
13. E.H. Kim, S.U. Kim, D.Y. Shin, and K.S. Choi Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP Oncogene 23 2004 446 456
14. S.M. Srinivasula, S. Gupta, P. Datta, Z. Zhang, R. Hegde, N. Cheong, T. Fernandes-Alnemri, and E.S. Alnemri Inhibitor of apoptosis proteins are substrates for the mitochondrial serine protease Omi/HtrA2 J. Biol. Chem. 278 2003 31469 31472
15. X.D. Zhang, X.Y. Zhang, C.P. Gray, T. Nguyen, and P. Hersey Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria Cancer Res. 61 2001 7339 7348
16. G.K. Scott, J.M. Dodson, P.A. Montgomery, R.M. Johnson, J.C. Sarup, W.L. Wong, A. Ullrich, H.M. Shepard, and C.C. Benz p185HER2 signal transduction in breast cancer cells J. Biol. Chem. 266 1991 14300 14305
17. V.R. Chazin, M. Kaleko, A.D. Miller, and D.J. Slamon Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor Oncogene 7 1992 1859 1866
18. Y.S. Kim, S.N. Konoplev, F. Montemurro, E. Hoy, T.L. Smith, G. Rondon, R.E. Champlin, A.A. Sahin, and N.T. Ueno HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation Clin. Cancer Res. 7 2001 4008 4012
19. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, D.E. Keith, W.J. Levin, S.G. Stuart, J. Udove, and A. Ullrich Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
20. H.M. Shepard, G.D. Lewis, J.C. Sarup, B.M. Fendly, D. Maneval, J. Mordenti, I. Figari, C.E. Kotts, M.A. Palladino Jr., and A. Ullrich Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic J. Clin. Immunol. 11 1991 117 127
21. J. Baselga, D. Tripathy, J. Mendelsohn, S. Baughman, C.C. Benz, L. Dantis, N.T. Sklarin, A.D. Seidman, C.A. Hudis, J. Moore, P.P. Rosen, T. Twaddell, I.C. Henderson, and L. Norton Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer Clin. Oncol. 14 1996 737 744
22. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, and L. Norton Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 New Engl. J. Med. 344 2001 783 792
23. A.D. Seidman, M.N. Fornier, F.J. Esteva, L. Tan, S. Kaptain, A. Bach, K.S. Panageas, C. Arroyo, V. Valero, and V. Currie Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification J. Clin. Oncol. 19 2001 2587 2595
24. C.L. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, L. Fehrenbacher, D.J. Slamon, M. Murphy, W.F. Novotny, M. Burchmore, S. Shak, and S.J. Stewart First-line Herceptin monotherapy in metastatic breast cancer Oncology 61 2001 37 42
25. C.L. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, L. Fehrenbacher, D.J. Slamon, M. Murphy, W.F. Novotny, M. Burchmore, S. Shak, S.J. Stewart, and M. Press Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J. Clin. Oncol. 20 2002 719 726
26. F. Cardoso, M.J. Piccart, V. Durbecq, and A. Di Leo Resistance to trastuzumab: a necessary evil or a temporary challenge? Clin. Breast Cancer 3 2002 247 259
27. H.A. Lane, A.B. Motoyama, I. Beuvink, and N.E. Hynes Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling Ann. Oncol. 12 Suppl 1 2000 S21 S22
28. F.M. Yakes, W. Chinratanalab, C.A. Ritter, W. King, S. Seelig, and C.L. Arteaga Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action Cancer Res. 62 2002 4132 4141
29. X.F. Le, F.X. Claret, A. Lammayot, L. Tian, D. Deshpande, R. LaPushin, A.M. Tari, and R.C. Bast Jr. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition J. Biol. Chem. 278 2003 23441 23450
30. S.K. Mohsin, H.L. Weiss, M.C. Gutierrez, G.C. Chamness, R. Schiff, M.P. Digiovanna, C.X. Wang, S.G. Hilsenbeck, C.K. Osborne, D.C. Allred, R. Elledge, and J.C. Chang Neoadjuvant trastuzumab induces apoptosis in primary breast cancers J. Clin. Oncol. 23 2005 2460 2468
31. J.F. Mineo, A. Bordron, I. Quintin-Roue, S. Loisel, K.L. Ster, V. Buhe, N. Lagarde, and C. Berthou Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas Br. J. Cancer 91 2004 1195 1199
32. M.X. Sliwkowski, J.A. Lofgren, G.D. Lewis, T.E. Hotaling, B.M. Fendly, and J.A. Fox Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) Semin. Oncol. 26 1999 60 70
33. W.E. Carson, R. Parihar, M.J. Lindemann, N. Personeni, J. Dierksheide, N.J. Meropol, J. Baselga, and M.A. Caligiuri Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells Eur. J. Immunol. 31 2001 3016 3025
34. M. Kubo, T. Morisaki, H. Kuroki, A. Tasaki, N. Yamanaka, K. Matsumoto, K. Nakamura, H. Onishi, E. Baba, and M. Katano Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer Anticancer Res. 23 2003 4443 4449
35. C.I. Spiridon, M.A. Ghetie, J. Uhr, R. Marches, J.L. Li, G.L. Shen, and E.S. Vitetta Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo Clin. Cancer Res. 8 2002 1720 1730
36. W. Liu, J. Li, and R.A. Roth Heregulin regulation of Akt/protein kinase B in breast cancer cells Biochem. Biophys. Res. Commun. 261 1999 897 903
37. S.R. Datta, H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, and M.E. Greenberg Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell 91 1997 231 241
38. L. del Peso, M. Gonzalez-Garcia, C. Page, R. Herrera, and G. Nunez Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt Science 278 1997 687 689
39. M. Cuello, S.A. Ettenberg, A.S. Clark, M.M. Keane, R.H. Posner, M.M. Nau, P.A. Dennis, and S. Lipkowitz Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2 Cancer Res. 61 2001 4892 4900
40. M. Plasilova, J. Zivny, J. Jelinek, R. Neuwirtova, J. Cermak, E. Necas, L. Andera, and T. Stopka TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors Leukemia 16 2002 67 73
41. P. Carter, L. Presta, C.M. Gorman, J.B. Ridgway, D. Henner, W.L. Wong, A.M. Rowland, C. Kotts, M.E. Carver, and H.M. Shepard Humanization of an anti-p185HER2 antibody for human cancer therapy Proc. Natl. Acad. Sci. USA 15 1992 4285 4289
42. R.M. Neve, H. Sutterluty, N. Pullen, H.A. Lane, J.M. Daly, W. Krek, and N.E. Hynes Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells Oncogene 19 2000 1647 1656
43. T.B. Deb, L. Su, L. Wong, E. Bonvini, A. Wells, M. David, and G.R. Johnson Epidermal growth factor (EGF) receptor kinase-independent signaling by EGF J. Biol. Chem. 276 2001 15554 15560
44. E.S. Kandel, and N. Hay The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB Exp. Cell. Res. 253 1999 210 229
45. B.M. Marte, D. Graus-Porta, M. Jeschke, D. Fabbro, N.E. Hynes, and D. Taverna NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells Oncogene 10 1995 167 175
46. Y. Tokuda, T. Watanabe, Y. Omuro, M. Ando, N. Katsumata, A. Okumura, M. Ohta, H. Fujii, Y. Sasaki, T. Niwa, and T. Tajima Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer Br. J. Cancer 81 1999 1419 1425
47. L. Yen, Z.R. Nie, X.L. You, S. Richard, B.C. Langton-Webster, and M.A. Alaoui-Jamali Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway Oncogene 14 1997 1827 1835
48. D. Yu, B. Liu, T. Jing, D. Sun, J.E. Price, S.E. Singletary, N. Ibrahim, G.N. Hortobagyi, and M.C. Hung Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol Oncogene 16 1998 2087 2094
49. Z. Zhou, S.F. Jia, M.C. Hung, and E.S. Kleinerman E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs Cancer Res. 61 2001 3394 3398
50. R.R. Zhou, S.F. Jia, Z. Zhou, Y. Wang, C.D. Bucana, and E.S. Kleinerman Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16 Cancer Gene Ther. 9 2002 407 413
51. K. Liang, Y. Lu, W. Jin, K.K. Ang, L. Milas, and Z. Fan Sensitization of breast cancer cells to radiation by trastuzumab Mol. Cancer Ther. 2 2003 1113 1120
52. B.P. Zhou, M.C. Hu, S.A. Miller, Z. Yu, W. Xia, S.Y. Lin, and M.C. Hung HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway J. Biol. Chem. 275 2000 8027 8031
53. T.S. Soderstrom, M. Poukkula, T.H. Holmstrom, K.M. Heiskanen, and J.E. Eriksson Mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in activated T cells abrogates TRAIL-induced apoptosis upstream of the mitochondrial amplification loop and caspase-8 J. Immunol. 169 2002 2851 2860
54. M. Sarker, C. Ruiz-Ruiz, G. Robledo, and A. Lopez-Rivas Stimulation of the mitogen-activated protein kinase pathway antagonizes TRAIL-induced apoptosis downstream of BID cleavage in human breast cancer MCF-7 cells Oncogene 21 2002 4323 4327
55. S.Y. Park, and D.W. Seol Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis Biochem. Biophys. Res. Commun. 5 2002 515 518
56. E.M. Gibson, E.S. Henson, N. Haney, J. Villanueva, and S.B. Gibson Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release Cancer Res. 62 2002 488 496
57. H. Thakkar, X. Chen, F. Tyan, S. Gim, H. Robinson, C. Lee, S.K. Pandey, C. Nwokorie, N. Onwudiwe, and R.K. Srivastava Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance J. Biol. Chem. 276 2001 38361 38369
58. K. Kandasamy, and R.K. Srivastava Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells Cancer Res. 62 2002 4929 4937
59. M.D. Pegram, G.E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras, and D.J. Slamon Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer J. Natl. Cancer Inst. 96 2004 739 749
60. S.B. Gibson, R. Oyer, A.C. Spalding, S.M. Anderson, and G.L. Johnson Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL Mol. Cell. Biol. 20 2000 205 212
61. M.A. Sheard, S. Uldrijan, and B. Vojtesek Role of p53 in regulating constitutive and X-radiation-inducible CD95 expression and function in carcinoma cells Cancer Res. 63 2003 7176 7184